Skip to main content

Table 1 Patient background

From: Comparison of kidney and hepatic outcomes among sodium-glucose cotransporter-2 inhibitors: a retrospective study using multiple propensity scores

 

IGZ

(n = 837)

EGZ

(n = 850)

CGZ

(n = 922)

DGZ

(n = 590)

TGZ

(n = 288)

LGZ

(n = 193)

DPP4i

(n = 7,172)

Age, year

55.2 ± 14.9

60.2 ± 13.9

58.0 ± 15.6

52.2 ± 17.0

46.8 ± 14.6

49.7 ± 17.7

69.5 ± 12.1

Sex, males/females

579/258

579/271

614/308

410/180

164/124

134/59

4,390/2,782

Height, cm

162.3 ± 9.8

161.5 ± 10.5

160.8 ± 11.0

162.1 ± 10.1

161.2 ± 10.8

161.7 ± 11.0

159.9 ± 10.0

Weight, kg

72.4 ± 17.1

70.9 ± 17.3

70.8 ± 18.0

72.9 ± 17.5

76.5 ± 17.4

73.2 ± 17.4

60.3 ± 13.5

BMI

27.5 ± 6.2

27.2 ± 6.1

27.4 ± 7.1

27.8 ± 6.7

29.6 ± 6.7

28.2 ± 6.7

23.5 ± 4.2

Diabetes duration, year

0.7 ± 1.3

1.4 ± 2.4

1.1 ± 1.4

1.5 ± 2.6

1.3 ± 1.6

1.5 ± 2.2

1.5 ± 2.4

DPP4i, + / − 

534/303

465/385

595/327

352/238

173/115

106/87

-

SU, + / − 

186/651

173/677

212/710

89/501

49/239

29/164

1,943/5,229

α-GI, + / − 

112/725

81/769

66/856

41/549

10/278

8/185

515/6,657

GL, + / − 

44/793

34/816

46/876

24/566

12/276

3/190

289/6,883

BG, + / − 

337/500

344/506

315/607

226/364

99/189

84/109

1,700/5,472

TZ, + / − 

56/781

67/783

42/880

34/556

10/278

12/181

130/7,042

Liver disease, + / − 

78/759

119/731

64/858

57/533

20/268

11/182

3,016/4,156

Renal disease, + / − 

66/771

99/751

70/852

49/541

33/255

11/182

2,719/4,453

Heart disease, + / − 

174/663

210/640

174/748

106/484

58/230

13/180

2,732/4,440

Cerebrovascular disease, + / − 

35/802

35/815

36/886

14/576

8/280

0/193

1,043/6,129

Hypertension, + / − 

183/654

243/607

165/757

124/466

55/233

26/167

2,678/4,494

Dyslipidemia, + / − 

228/609

281/569

193/729

164/426

51/237

26/167

2,421/4,751

HbA1c, %

8.3 ± 1.8

8.1 ± 1.7

7.8 ± 1.6

8.2 ± 1.7

8.4 ± 1.9

8.4 ± 2.0

8.0 ± 2.2

eGFR, mL/min/1.73m2

67.1 ± 29.7

64.4 ± 28.0

64.3 ± 28.7

61.5 ± 28.5

61.3 ± 33.2

56.8 ± 26.5

63.9 ± 27.6

AST, IU/L

30.4 ± 18.9

31.3 ± 17.1

31.1 ± 25.1

30.9 ± 18.1

30.7 ± 19.3

31.9 ± 16.9

32.7 ± 65.1

ALT, IU/L

34.8 ± 26.5

33.9 ± 22.2

34.0 ± 24.6

36.2 ± 26.9

36.6 ± 26.6

37.5 ± 24.9

31.1 ± 53.4

HDL-C, mg/dL

44.8 ± 17.5

48.4 ± 16.6

49.5 ± 16.7

49.0 ± 17.9

49.6 ± 17.7

47.0 ± 16.3

49.4 ± 15.8

LDL-C, mg/dL

116.4 ± 37.2

115.6 ± 37.4

114.9 ± 36.8

114.3 ± 34.9

120.5 ± 39.8

119 ± 34.9

109.5 ± 34.0

TG, mg/dL

166.7 ± 189.3

165.7 ± 123.2

158.5 ± 93.7

153.4 ± 81.1

180.5 ± 160.0

169.6 ± 92.6

154.1 ± 141.5

  1. Data are expressed as the mean ± standard deviation (SD)
  2. IGZ Ipragliflozin, EGZ Empagliflozin, CGZ Canagliflozin, DGZ Dapagliflozin, TGZ Tofogliflozin, LGZ Luseogliflozin, BMI Body mass index, DPP-4i Dipeptidyl peptidase-4 inhibitor, SU Sulfonylurea, GL Glinide, α-GI α-glucosidase inhibitor, BG Biguanide, TZ Thiazolidinediones, HbA1c Glycated hemoglobin, eGFR Estimated glomerular filtration rate, AST Aspartate aminotransferase, ALT Alanine aminotransferase, HDL-C High-density lipoprotein-cholesterol, LDL-C Low-density lipoprotein-cholesterol, TG Triglyceride
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us